Clinical Trials Browser

Enrolling by invitation × Urinary Bladder Neoplasms × 1 year × Clear all

Urinary Bladder Neoplasms

NCT07218003 2026-05-04

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05195515 2026-03-03

CONQUER

Enrolling by invitation

2,000 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06243510 2026-01-28

CARE

Phase NA Enrolling by invitation

90 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07148765 2025-09-26

Use of Wearables Following Cystectomy- Part II

Phase NA Enrolling by invitation

50 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urinary Bladder, Neurogenic

NCT07180121 2025-09-18

CaRe

Enrolling by invitation

200 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05739071 2025-09-11

JING SI HERBAL TEA and Urinary Tract Symptoms in Bladder Cancer

Phase NA Enrolling by invitation

100 enrolled

Genitourinary

Urinary Bladder Neoplasms, Lower Urinary Tract Symptoms

NCT07091565 2025-08-03

SPARC

Enrolling by invitation

60 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Clinical Trials

VIABLE

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

CONQUER

CARE

Use of Wearables Following Cystectomy- Part II

CaRe

JING SI HERBAL TEA and Urinary Tract Symptoms in Bladder Cancer

SPARC